195 related articles for article (PubMed ID: 23511135)
21. Monitoring in real time the cytotoxic effect of Clostridium difficile upon the intestinal epithelial cell line HT29.
Valdés L; Gueimonde M; Ruas-Madiedo P
J Microbiol Methods; 2015 Dec; 119():66-73. PubMed ID: 26436983
[TBL] [Abstract][Full Text] [Related]
22. Clostridium difficile toxins may augment bacterial penetration of intestinal epithelium.
Feltis BA; Kim AS; Kinneberg KM; Lyerly DL; Wilkins TD; Erlandsen SL; Wells CL
Arch Surg; 1999 Nov; 134(11):1235-41; discussion 1241-2. PubMed ID: 10555639
[TBL] [Abstract][Full Text] [Related]
23. Gender dimorphism in the gut: mucosal protection by estrogen stimulation of IgA transcytosis.
Diebel ME; Diebel LN; Liberati DM
J Trauma; 2011 Aug; 71(2):474-9. PubMed ID: 21825949
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization.
Siddiqui F; O'Connor JR; Nagaro K; Cheknis A; Sambol SP; Vedantam G; Gerding DN; Johnson S
J Infect Dis; 2012 Jan; 205(1):128-33. PubMed ID: 22124129
[TBL] [Abstract][Full Text] [Related]
25. Epithelial cell I kappa B-kinase beta has an important protective role in Clostridium difficile toxin A-induced mucosal injury.
Chae S; Eckmann L; Miyamoto Y; Pothoulakis C; Karin M; Kagnoff MF
J Immunol; 2006 Jul; 177(2):1214-20. PubMed ID: 16818780
[TBL] [Abstract][Full Text] [Related]
26. The distribution and density of Clostridium difficile toxin receptors on the intestinal mucosa of neonatal pigs.
Keel MK; Songer JG
Vet Pathol; 2007 Nov; 44(6):814-22. PubMed ID: 18039894
[TBL] [Abstract][Full Text] [Related]
27. New trends in Clostridium difficile virulence and pathogenesis.
Denève C; Janoir C; Poilane I; Fantinato C; Collignon A
Int J Antimicrob Agents; 2009 Mar; 33 Suppl 1():S24-8. PubMed ID: 19303565
[TBL] [Abstract][Full Text] [Related]
28. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.
Akerlund T; Svenungsson B; Lagergren A; Burman LG
J Clin Microbiol; 2006 Feb; 44(2):353-8. PubMed ID: 16455883
[TBL] [Abstract][Full Text] [Related]
29. Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment.
Mahida YR; Makh S; Hyde S; Gray T; Borriello SP
Gut; 1996 Mar; 38(3):337-47. PubMed ID: 8675084
[TBL] [Abstract][Full Text] [Related]
30. H2 blockers decrease gut mucus production and lead to barrier dysfunction in vitro.
Diebel LN; Liberati DM; Hall-Zimmerman L
Surgery; 2011 Oct; 150(4):736-43. PubMed ID: 22000186
[TBL] [Abstract][Full Text] [Related]
31. Clostridium difficile toxin: cytoskeletal changes and lactate dehydrogenase release in hepatocytes.
Grossmann EM; Longo WE; Kaminski DL; Smith GS; Murphy CE; Durham RL; Shapiro MJ; Norman JG; Mazuski JE
J Surg Res; 2000 Feb; 88(2):165-72. PubMed ID: 10644484
[TBL] [Abstract][Full Text] [Related]
32. Human intestinal epithelial and smooth muscle cells are potent producers of IL-6.
Ng EK; Panesar N; Longo WE; Shapiro MJ; Kaminski DL; Tolman KC; Mazuski JE
Mediators Inflamm; 2003 Feb; 12(1):3-8. PubMed ID: 12745542
[TBL] [Abstract][Full Text] [Related]
33. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
[TBL] [Abstract][Full Text] [Related]
34. Clostridium difficile and the disease it causes.
Norén T
Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000
[TBL] [Abstract][Full Text] [Related]
35. The role of toxin A and toxin B in the virulence of Clostridium difficile.
Carter GP; Rood JI; Lyras D
Trends Microbiol; 2012 Jan; 20(1):21-9. PubMed ID: 22154163
[TBL] [Abstract][Full Text] [Related]
36. Effects of Clostridium difficile toxins on epithelial cell barrier.
Pothoulakis C
Ann N Y Acad Sci; 2000; 915():347-56. PubMed ID: 11193598
[TBL] [Abstract][Full Text] [Related]
37. Early tranexamic acid administration: A protective effect on gut barrier function following ischemia/reperfusion injury.
Diebel ME; Diebel LN; Manke CW; Liberati DM; Whittaker JR
J Trauma Acute Care Surg; 2015 Dec; 79(6):1015-22. PubMed ID: 26317817
[TBL] [Abstract][Full Text] [Related]
38. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
Kyne L; Warny M; Qamar A; Kelly CP
N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
[TBL] [Abstract][Full Text] [Related]
39. Clostridium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells.
Castagliuolo I; Keates AC; Wang CC; Pasha A; Valenick L; Kelly CP; Nikulasson ST; LaMont JT; Pothoulakis C
J Immunol; 1998 Jun; 160(12):6039-45. PubMed ID: 9637520
[TBL] [Abstract][Full Text] [Related]
40. Active and Secretory IgA-Coated Bacterial Fractions Elucidate Dysbiosis in Clostridium difficile Infection.
Džunková M; Moya A; Vázquez-Castellanos JF; Artacho A; Chen X; Kelly C; D'Auria G
mSphere; 2016; 1(3):. PubMed ID: 27303742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
